Filing Flows › Alpha Teknova (TKNO) › Q2 2026 › vs Q1 2026
Alpha Teknova (TKNO) Q2 2026 vs Q1 2026 (quarter over quarter)
Alpha Teknova's revenue rose $1.1M (+10%) from $11.1M in Q1 2026 to $12.2M in Q2 2026. The biggest changes: Lab Essentials +$789K (+9%); Clinical Solutions +$283K (+13%); Other Product +$36K (+7%).
Alpha Teknova, Q2 2026: revenue $12.2M (+18% year over year), operating margin -23.7%, net loss $3.2M, operating cash flow −$471K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Lab Essentials | $9.2M | $8.4M | $789K | +9% |
| Clinical Solutions | $2.4M | $2.1M | $283K | +13% |
| Other Product | $573K | $537K | $36K | +7% |
| Revenue | $12.2M | $11.1M | $1.1M | +10% |
| Net loss | $3.2M | $4.6M | −$1.4M | -30% |
| Costs & expenses | $15.4M | $15.6M | −$277K | -2% |
| Operating costs | $15.1M | $15.4M | −$300K | -2% |
| Interest & other, net | $250K | $210K | $40K | +19% |
| Income tax | $30K | $47K | −$17K | -36% |
| Cost of revenue | $7.3M | $7.3M | $7K | +0.1% |
| Research & development | $554K | $609K | −$55K | -9% |
| Sales & marketing | $2.1M | $2.1M | −$6K | -0.3% |
| General & admin | $4.8M | $5.1M | −$246K | -5% |
| Other operating costs | $287K | $287K | $0 | 0% |
| Operating cash sources | $3.2M | $4.6M | −$1.4M | -30% |
| Depreciation & amortization | $1.6M | $1.6M | $17K | +1% |
| Share-based compensation | $622K | $695K | −$73K | -11% |
| Working capital & other | $484K | −$1.1M | $1.6M | — |
| Cash used in operations | $471K | $3.4M | −$2.9M | -86% |
| Net loss absorbed | $3.2M | $4.6M | −$1.4M | -30% |
Questions
How much did Alpha Teknova's revenue grow quarter over quarter in Q2 2026?
Alpha Teknova's revenue rose $1.1M (+10%) from $11.1M in Q1 2026 to $12.2M in Q2 2026.
What drove Alpha Teknova's revenue change in Q2 2026?
Lab Essentials +$789K (+9%); Clinical Solutions +$283K (+13%); Other Product +$36K (+7%).